TNF and COVID-19: Current recommendations are to use lower doses of prednisone (20 mg/d) or budesonide and to avoid thiopurines, methotrexate, and tofacitinib, and postpone anti-TNF therapies, ustekinumab, and vedolizumab for 2 weeks while monitoring the development of COVID-19.